Prospective Phase II Study of a High Dose, Short Course Regimen (R-CODOX-M/IVAC) Including CNS Penetration and Intensive IT Prophylaxis in HIV-Associated Burkitt's and Atypical Burkitt's Lymphoma.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Folinic acid; Hydrocortisone; Ifosfamide; Methotrexate; Rituximab; Vincristine
- Indications Burkitt's lymphoma
- Focus Therapeutic Use
- 06 Jun 2018 Biomarkers information updated
- 20 May 2011 Planned end date changed from 1 Nov 2010 to 1 Jul 2013 as reported by ClinicalTrials.gov.
- 18 May 2010 Planned end date changed from 1 Dec 2007 to 1 Nov 2010 as reported by ClinicalTrials.gov.